IL17A and B-cell chronic lymphocytic leukemia: In CLL patients, IL-17A expression was more diverse and significantly higher in patients in Rai Stage 0 (median, 12.11%) as compared to those in Rai Stages I–II (median, 8.11%) and III–IV (median, 5.15%) (Figure 3B).